Aarhus University Seal

Anders Hammerich Riis

Validating registry data on statins prescriptions by blood measurements

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Validating registry data on statins prescriptions by blood measurements. / Riis, Anders H; Erichsen, Rune; Ostenfeld, Eva B et al.

In: Pharmacoepidemiology and Drug Safety, Vol. 28, No. 5, 05.2019, p. 609-615.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Riis AH, Erichsen R, Ostenfeld EB, Højskov CS, Thorlacius-Ussing O, Stender MT et al. Validating registry data on statins prescriptions by blood measurements. Pharmacoepidemiology and Drug Safety. 2019 May;28(5):609-615. doi: 10.1002/pds.4700

Author

Riis, Anders H ; Erichsen, Rune ; Ostenfeld, Eva B et al. / Validating registry data on statins prescriptions by blood measurements. In: Pharmacoepidemiology and Drug Safety. 2019 ; Vol. 28, No. 5. pp. 609-615.

Bibtex

@article{cf84d0bfb2d14efdb94be4380569f97c,
title = "Validating registry data on statins prescriptions by blood measurements",
abstract = "PURPOSE: To validate prescription registry data as a measurement of adherence to statins through a direct method using assays for selected statins in serial blood samples collected from two prospective cohorts of Danish colorectal cancer patients.METHODS: We linked information on statin prescriptions from the Aarhus University Prescription Database with the cancer cohorts from Aalborg University Hospital. For statin-prescribed patients, we calculated a prescription window covering the anticipated duration of the prescription. For each statin-prescribed patient with at least one blood sample in a prescription window, we selected without replacement a never-statin-prescribed patient matched on sex, age, and calendar year of surgery. Each of the selected blood samples were analyzed using assays to detect statins. We calculated the positive and negative predictive value of the prescription registry reporting using the assay result as the gold standard.RESULTS: We identified 73 ever-statin-prescribed patients with a total of 253 blood samples and 74 blood samples among never-statin-prescribed patients. The positive predictive value for prescribed patients, with presence of statins in at least one blood sample as the gold standard, was 93% (95% CI, 86%-97%) and the negative predictive value was 93% (95% CI, 86%-97%). Stratified results did not reveal substantial differences in predictive values. Fifty-two (71%) of the statin-prescribed patients had statins in every blood sample, suggesting continuous adherence.CONCLUSION: This study showed a high adherence with treatment with statins among colorectal cancer patients.",
keywords = "adherence, health administrative data, pharmacoepidemiology, statins",
author = "Riis, {Anders H} and Rune Erichsen and Ostenfeld, {Eva B} and H{\o}jskov, {Carsten S} and Ole Thorlacius-Ussing and Stender, {Mogens Tornby} and Lash, {Timothy L} and M{\o}ller, {Holger Jon}",
note = "{\textcopyright} 2019 John Wiley & Sons, Ltd.",
year = "2019",
month = may,
doi = "10.1002/pds.4700",
language = "English",
volume = "28",
pages = "609--615",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "JohnWiley & Sons Ltd.",
number = "5",

}

RIS

TY - JOUR

T1 - Validating registry data on statins prescriptions by blood measurements

AU - Riis, Anders H

AU - Erichsen, Rune

AU - Ostenfeld, Eva B

AU - Højskov, Carsten S

AU - Thorlacius-Ussing, Ole

AU - Stender, Mogens Tornby

AU - Lash, Timothy L

AU - Møller, Holger Jon

N1 - © 2019 John Wiley & Sons, Ltd.

PY - 2019/5

Y1 - 2019/5

N2 - PURPOSE: To validate prescription registry data as a measurement of adherence to statins through a direct method using assays for selected statins in serial blood samples collected from two prospective cohorts of Danish colorectal cancer patients.METHODS: We linked information on statin prescriptions from the Aarhus University Prescription Database with the cancer cohorts from Aalborg University Hospital. For statin-prescribed patients, we calculated a prescription window covering the anticipated duration of the prescription. For each statin-prescribed patient with at least one blood sample in a prescription window, we selected without replacement a never-statin-prescribed patient matched on sex, age, and calendar year of surgery. Each of the selected blood samples were analyzed using assays to detect statins. We calculated the positive and negative predictive value of the prescription registry reporting using the assay result as the gold standard.RESULTS: We identified 73 ever-statin-prescribed patients with a total of 253 blood samples and 74 blood samples among never-statin-prescribed patients. The positive predictive value for prescribed patients, with presence of statins in at least one blood sample as the gold standard, was 93% (95% CI, 86%-97%) and the negative predictive value was 93% (95% CI, 86%-97%). Stratified results did not reveal substantial differences in predictive values. Fifty-two (71%) of the statin-prescribed patients had statins in every blood sample, suggesting continuous adherence.CONCLUSION: This study showed a high adherence with treatment with statins among colorectal cancer patients.

AB - PURPOSE: To validate prescription registry data as a measurement of adherence to statins through a direct method using assays for selected statins in serial blood samples collected from two prospective cohorts of Danish colorectal cancer patients.METHODS: We linked information on statin prescriptions from the Aarhus University Prescription Database with the cancer cohorts from Aalborg University Hospital. For statin-prescribed patients, we calculated a prescription window covering the anticipated duration of the prescription. For each statin-prescribed patient with at least one blood sample in a prescription window, we selected without replacement a never-statin-prescribed patient matched on sex, age, and calendar year of surgery. Each of the selected blood samples were analyzed using assays to detect statins. We calculated the positive and negative predictive value of the prescription registry reporting using the assay result as the gold standard.RESULTS: We identified 73 ever-statin-prescribed patients with a total of 253 blood samples and 74 blood samples among never-statin-prescribed patients. The positive predictive value for prescribed patients, with presence of statins in at least one blood sample as the gold standard, was 93% (95% CI, 86%-97%) and the negative predictive value was 93% (95% CI, 86%-97%). Stratified results did not reveal substantial differences in predictive values. Fifty-two (71%) of the statin-prescribed patients had statins in every blood sample, suggesting continuous adherence.CONCLUSION: This study showed a high adherence with treatment with statins among colorectal cancer patients.

KW - adherence

KW - health administrative data

KW - pharmacoepidemiology

KW - statins

U2 - 10.1002/pds.4700

DO - 10.1002/pds.4700

M3 - Journal article

C2 - 30779395

VL - 28

SP - 609

EP - 615

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 5

ER -